Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qiwei Suantengguo Wan is a traditional Tibetan medicine produced by Xizang Ganlu Tibetan Medicine. It is an oral pill formulation composed of seven ingredients, including *Embelia ribes* (Suantengguo), *Inula racemosa*, *Terminalia chebula*, *Terminalia bellirica*, *Phyllanthus emblica*, *Sal ammoniac*, and *Ulmus macrocarpa*. The medicine is primarily indicated for the treatment of intestinal parasite infestations (helminthiasis), abdominal pain caused by parasitic accumulation, and indigestion. In the framework of Tibetan medicine, it is used to regulate imbalances in the digestive system and eliminate 'worm' accumulation. It is an approved pharmaceutical product in China, registered under the National Drug License Number Z54020073.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qiwei Suantengguo Wan.